Amalus Therapeutics SRL
Ouverture de faillite 1.6 FTEAmalus Therapeutics reported total assets of 160,051 € at the end of the 2024 financial year (annual accounts filed with the NBB on 07 Jul 2025), with 1.6 full-time equivalent.
The score of Amalus Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2024
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Amalus Therapeutics's annual accounts
| 2024 | |
|---|---|
| Net result | −341,736 € |
| Equity | −331,736 € |
| Cash | 123,416 € |
| EBITDA | −4,632 € |
| Total assets | 160,051 € |
Filed annual accounts
- Year ended 31 Dec 2024filed on 07 Jul 2025
Amalus Therapeutics's financial analysis
- Solvency-207.3%sector median: 56.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Amalus Therapeutics
Amalus Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0803.929.268
- VAT number
- BE0803929268
- Peppol
- Registered · 0208:0803929268 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 13 Jul 2023
- Registered office
- 9052 Ghent
- Size
- Micro · 1.6 FTE
- Latest accounts
- 2024 · filed on 07 Jul 2025
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
Amalus Therapeutics (SRL) has been based in Ghent since 2023, active in: manufacture of basic pharmaceutical products. For 2024, it reports a net loss of 341,736 € and equity of −331,736 €; its revenue is not published. With 1.6 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at -207.3%, below the median of its sector (56.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Amalus Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- GRNR Invest Manufacture of basic pharmaceutical products Zemst · balance sheet €2.26m
- Inchinn Therapeutics Manufacture of basic pharmaceutical products Charleroi · balance sheet 51,394 €
- Grand Medical (Europe) Research and experimental development on natural sciences and engineering Niel · balance sheet 135,260 €
- Attito Management Manufacture of pharmaceutical preparations Kapelle-op-den-Bos · balance sheet 131,498 €
- Make IT Work Consulting Manufacture of basic pharmaceutical products Hamois · balance sheet 220,980 €
- Intibio Manufacture of pharmaceutical preparations Bree · balance sheet 407,778 €
- Mentana DX Research and experimental development on natural sciences and engineering Evergem · balance sheet 229,998 €
- Clinical Research Vanackere Manufacture of basic pharmaceutical products Tielt-Winge · balance sheet 263,927 €
Frequently asked questions about Amalus Therapeutics
What is the revenue of Amalus Therapeutics?
Amalus Therapeutics files its accounts in a format where revenue is optional: it is not published for 2024.
What is the VAT number of Amalus Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0803929268 for Amalus Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0803.929.268.
Where is the registered office of Amalus Therapeutics?
According to the CBE register, the registered office of Amalus Therapeutics is in 9052 Ghent.
What is the equity of Amalus Therapeutics?
At the close of the 2024 financial year, the equity of Amalus Therapeutics amounts to -331,736 €, a solvency of -207.3% of total assets.
How many people work at Amalus Therapeutics?
1.6 full-time equivalents on average according to the 2024 social balance sheet.
Who manages Amalus Therapeutics?
The register lists 5 active mandates at Amalus Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Amalus Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →